Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Jun;118(3):659–664. doi: 10.1111/j.1476-5381.1996.tb15451.x

Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats.

O Feron 1, S Salomone 1, T Godfraind 1
PMCID: PMC1909705  PMID: 8762091

Abstract

1. The tissue-protective effects of calcium channel blockers in hypertension are not well dissociated from their effect on systolic blood pressure (SBP). We have previously shown that lacidipine, a dihydropyridine-type calcium antagonist, reduced the cardiac hypertrophy and the cardiac endothelin-1 (ET-1) gene overexpression occurring in salt-loaded stroke-prone spontaneously hypertensive rats (SL-SHRSP), an effect occurring without systolic blood pressure (SBP) change. In the present study, we have examined whether this action was dose-related and if it could be associated with ET receptor changes. The action of lacidipine was also examined in control SHRSP and in Wistar Kyoto rats (WKY). 2. The daily dose of 0.3 mg kg-1 lacidipine which did not lower SBP but significantly prevented ventricle hypertrophy and cardiac preproET-1-mRNA expression in SL-SHRSP was inactive in control SHRSP. With the higher dose of lacidipine (1 mg kg-1 day-1), we observed a further reduction of cardiac hypertrophy and of ET-1 gene expression in SL-SHRSP and a significant effect on those parameters in control SHRSP but only a small reduction of SBP in both groups. 3. In WKY, salt loading did not induce change in SBP or increase of cardiac ET-1 gene expression and ventricle mass. In these normotensive rats, lacidipine (1 mg kg-1 day-1) did not modulate the basal preproET-1-mRNA expression and did not affect SBP or heart weight. 4. The maximum binding capacity (Bmax) and the dissociation constant (KD) of [125I]-ET-1 binding and the relative proportion of low- and high-affinity binding sites for ET-3 were not significantly affected by salt loading or lacidipine treatment in SHRSP. 5. These results show that lacidipine exerted a dose-related inhibition of ventricle hypertrophy and preproET-1-mRNA expression in SHRSP and indicate that this effect was unrelated to SBP changes. The dose-dependency of this inhibition suggests that salt-induced cardiac hypertrophy could be related to ET-1 gene overexpression. The results further show that ET receptor changes are not involved in the pathophysiological process studied here.

Full text

PDF
659

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  2. Cristofori P., Terron A., Micheli D., Bertolini G., Gaviraghi G., Carpi C. Vascular protection of lacidipine in salt-loaded Dahl-S rats at nonsustained antihypertensive doses. J Cardiovasc Pharmacol. 1991;17 (Suppl 4):S75–S86. [PubMed] [Google Scholar]
  3. De Keulenaer G. W., Andries L. J., Sys S. U., Brutsaert D. L. Endothelin-mediated positive inotropic effect induced by reactive oxygen species in isolated cardiac muscle. Circ Res. 1995 May;76(5):878–884. doi: 10.1161/01.res.76.5.878. [DOI] [PubMed] [Google Scholar]
  4. Feron O., Salomone S., Godfraind T. Influence of salt loading on the cardiac and renal preproendothelin-1 mRNA expression in stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun. 1995 Apr 6;209(1):161–166. doi: 10.1006/bbrc.1995.1484. [DOI] [PubMed] [Google Scholar]
  5. Feron O., Salomone S., Godfraind T. Inhibition by lacidipine of salt-dependent cardiac hypertrophy and endothelin gene expression in stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun. 1995 May 5;210(1):219–224. doi: 10.1006/bbrc.1995.1649. [DOI] [PubMed] [Google Scholar]
  6. Fu L. X., Sun X. Y., Hedner T., Feng Q. P., Liang Q. M., Hoebeke J., Hjalmarson A. Decreased density of mesenteric arteries but not of myocardial endothelin receptors and function in rats with chronic ischemic heart failure. J Cardiovasc Pharmacol. 1993 Aug;22(2):177–182. doi: 10.1097/00005344-199308000-00001. [DOI] [PubMed] [Google Scholar]
  7. Gaviraghi G., Micheli D., Terron A., Cristofori P. Lacidipine: prevention of vascular damage induced by hypertension. J Cardiovasc Pharmacol. 1991;18 (Suppl 11):S7–12. doi: 10.1097/00005344-199102001-00002. [DOI] [PubMed] [Google Scholar]
  8. Godfraind T., Miller R., Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev. 1986 Dec;38(4):321–416. [PubMed] [Google Scholar]
  9. Hayzer D. J., Cicila G., Cockerham C., Griendling K. K., Delafontaine P., Ng S. C., Runge M. S. Endothelin A and B receptors are down-regulated in the hearts of hypertensive rats. Am J Med Sci. 1994 Mar;307(3):222–227. doi: 10.1097/00000441-199403000-00010. [DOI] [PubMed] [Google Scholar]
  10. Hirata Y., Yoshimi H., Takaichi S., Yanagisawa M., Masaki T. Binding and receptor down-regulation of a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. FEBS Lett. 1988 Oct 24;239(1):13–17. doi: 10.1016/0014-5793(88)80536-2. [DOI] [PubMed] [Google Scholar]
  11. Hori S., Komatsu Y., Shigemoto R., Mizuno N., Nakanishi S. Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology. 1992 Apr;130(4):1885–1895. doi: 10.1210/endo.130.4.1312429. [DOI] [PubMed] [Google Scholar]
  12. Ishikawa T., Li L. M., Shinmi O., Kimura S., Yanagisawa M., Goto K., Masaki T. Characteristics of binding of endothelin-1 and endothelin-3 to rat hearts. Developmental changes in mechanical responses and receptor subtypes. Circ Res. 1991 Oct;69(4):918–926. doi: 10.1161/01.res.69.4.918. [DOI] [PubMed] [Google Scholar]
  13. Ito H., Hirata Y., Adachi S., Tanaka M., Tsujino M., Koike A., Nogami A., Murumo F., Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993 Jul;92(1):398–403. doi: 10.1172/JCI116579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ito H., Hirata Y., Hiroe M., Tsujino M., Adachi S., Takamoto T., Nitta M., Taniguchi K., Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res. 1991 Jul;69(1):209–215. doi: 10.1161/01.res.69.1.209. [DOI] [PubMed] [Google Scholar]
  15. Ito H., Hiroe M., Hirata Y., Fujisaki H., Adachi S., Akimoto H., Ohta Y., Marumo F. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation. 1994 May;89(5):2198–2203. doi: 10.1161/01.cir.89.5.2198. [DOI] [PubMed] [Google Scholar]
  16. Kanno K., Hirata Y., Tsujino M., Imai T., Shichiri M., Ito H., Marumo F. Up-regulation of ETB receptor subtype mRNA by angiotensin II in rat cardiomyocytes. Biochem Biophys Res Commun. 1993 Aug 16;194(3):1282–1287. doi: 10.1006/bbrc.1993.1962. [DOI] [PubMed] [Google Scholar]
  17. Kim S., Ohta K., Hamaguchi A., Omura T., Yukimura T., Miura K., Inada Y., Ishimura Y., Chatani F., Iwao H. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther. 1995 Apr;273(1):509–515. [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980 Mar 1;102(2):344–352. doi: 10.1016/0003-2697(80)90165-7. [DOI] [PubMed] [Google Scholar]
  20. Larivière R., Day R., Schiffrin E. L. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1993 Jun;21(6 Pt 2):916–920. doi: 10.1161/01.hyp.21.6.916. [DOI] [PubMed] [Google Scholar]
  21. Leenen F. H., Smith D. L., Farkas R. M., Reeves R. A., Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med. 1987 May;82(5):969–978. doi: 10.1016/0002-9343(87)90160-4. [DOI] [PubMed] [Google Scholar]
  22. Linz W., Henning R., Schölkens B. A. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens Suppl. 1991 Dec;9(6):S400–S401. [PubMed] [Google Scholar]
  23. Messerli F. H., Ketelhut R. Left ventricular hypertrophy: an independent risk factor. J Cardiovasc Pharmacol. 1991;17 (Suppl 4):S59–S67. [PubMed] [Google Scholar]
  24. Misra R. P., Bonni A., Miranti C. K., Rivera V. M., Sheng M., Greenberg M. E. L-type voltage-sensitive calcium channel activation stimulates gene expression by a serum response factor-dependent pathway. J Biol Chem. 1994 Oct 14;269(41):25483–25493. [PubMed] [Google Scholar]
  25. Molenaar P., O'Reilly G., Sharkey A., Kuc R. E., Harding D. P., Plumpton C., Gresham G. A., Davenport A. P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993 Mar;72(3):526–538. doi: 10.1161/01.res.72.3.526. [DOI] [PubMed] [Google Scholar]
  26. Morgan H. E., Baker K. M. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation. 1991 Jan;83(1):13–25. doi: 10.1161/01.cir.83.1.13. [DOI] [PubMed] [Google Scholar]
  27. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  28. Murphy T. H., Worley P. F., Baraban J. M. L-type voltage-sensitive calcium channels mediate synaptic activation of immediate early genes. Neuron. 1991 Oct;7(4):625–635. doi: 10.1016/0896-6273(91)90375-a. [DOI] [PubMed] [Google Scholar]
  29. Nara Y., Nabika T., Ikeda K., Sawamura M., Endo J., Yamori Y. Blood pressure cosegregates with a microsatellite of angiotensin I converting enzyme (ACE) in F2 generation from a cross between original normotensive Wistar-Kyoto rat (WKY) and stroke-prone spontaneously hypertensive rat (SHRSP). Biochem Biophys Res Commun. 1991 Dec 31;181(3):941–946. doi: 10.1016/0006-291x(91)92027-h. [DOI] [PubMed] [Google Scholar]
  30. Noel F., Godfraind T. Heterogeneity of ouabain specific binding sites and (Na+ + K+)-ATPase inhibition in microsomes from rat heart. Biochem Pharmacol. 1984 Jan 1;33(1):47–53. doi: 10.1016/0006-2952(84)90369-1. [DOI] [PubMed] [Google Scholar]
  31. Paul M., Zintz M., Böcker W., Dyer M. Characterization and functional analysis of the rat endothelin-1 promoter. Hypertension. 1995 Apr;25(4 Pt 2):683–693. doi: 10.1161/01.hyp.25.4.683. [DOI] [PubMed] [Google Scholar]
  32. Peter M. G., Davenport A. P. Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol. 1995 Jan;114(2):297–302. doi: 10.1111/j.1476-5381.1995.tb13226.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Roth M., Keul R., Emmons L. R., Hörl W. H., Block L. H. Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4071–4075. doi: 10.1073/pnas.89.9.4071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sakurai T., Morimoto H., Kasuya Y., Takuwa Y., Nakauchi H., Masaki T., Goto K. Level of ETB receptor mRNA is down-regulated by endothelins through decreasing the intracellular stability of mRNA molecules. Biochem Biophys Res Commun. 1992 Jul 15;186(1):342–347. doi: 10.1016/s0006-291x(05)80813-7. [DOI] [PubMed] [Google Scholar]
  35. Sakurai T., Yanagisawa M., Inoue A., Ryan U. S., Kimura S., Mitsui Y., Goto K., Masaki T. cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun. 1991 Feb 28;175(1):44–47. doi: 10.1016/s0006-291x(05)81197-0. [DOI] [PubMed] [Google Scholar]
  36. Salomone S., Godfraind T. Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle. Br J Pharmacol. 1993 May;109(1):100–106. doi: 10.1111/j.1476-5381.1993.tb13537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schiffrin E. L. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension. 1995 Jun;25(6):1135–1143. doi: 10.1161/01.hyp.25.6.1135. [DOI] [PubMed] [Google Scholar]
  38. Shibota M., Nagaoka A., Shino A., Fujita T. Renin-angiotensin system in stroke-prone spontaneously hypertensive rats. Am J Physiol. 1979 Mar;236(3):H409–H416. doi: 10.1152/ajpheart.1979.236.3.H409. [DOI] [PubMed] [Google Scholar]
  39. Shudo C., Masuda Y., Sugita H., Furukawa S., Hayashi K., Hirata H., Tanaka S., Tomita K. Renal protective effect of efonidipine hydrochloride (NZ-105), a new calcium antagonist, in spontaneously hypertensive rats. Gen Pharmacol. 1994 Dec;25(8):1567–1575. doi: 10.1016/0306-3623(94)90356-5. [DOI] [PubMed] [Google Scholar]
  40. Stasch J. P., Hirth-Dietrich C., Frobel K., Wegner M. Prolonged endothelin blockade reduces hypertension and cardiac hypertrophy in SHR-SP. J Cardiovasc Pharmacol. 1995;26 (Suppl 3):S436–S438. [PubMed] [Google Scholar]
  41. Stier C. T., Jr, Benter I. F., Ahmad S., Zuo H. L., Selig N., Roethel S., Levine S., Itskovitz H. D. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension. 1989 Feb;13(2):115–121. doi: 10.1161/01.hyp.13.2.115. [DOI] [PubMed] [Google Scholar]
  42. Stier C. T., Jr, Chander P., Gutstein W. H., Levine S., Itskovitz H. D. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens. 1991 Aug;4(8):680–687. doi: 10.1093/ajh/4.8.680. [DOI] [PubMed] [Google Scholar]
  43. Sung C. P., Arleth A. J., Storer B. L., Ohlstein E. H. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther. 1994 Oct;271(1):429–437. [PubMed] [Google Scholar]
  44. Suzuki T., Hoshi H., Mitsui Y. Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. FEBS Lett. 1990 Jul 30;268(1):149–151. doi: 10.1016/0014-5793(90)80995-u. [DOI] [PubMed] [Google Scholar]
  45. Volpe M., Camargo M. J., Mueller F. B., Campbell W. G., Jr, Sealey J. E., Pecker M. S., Sosa R. E., Laragh J. H. Relation of plasma renin to end organ damage and to protection of K+ feeding in stroke-prone hypertensive rats. Hypertension. 1990 Mar;15(3):318–326. doi: 10.1161/01.hyp.15.3.318. [DOI] [PubMed] [Google Scholar]
  46. van Amsterdam F. T., Roveri A., Maiorino M., Ratti E., Ursini F. Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Radic Biol Med. 1992;12(3):183–187. doi: 10.1016/0891-5849(92)90025-c. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES